The therapeutic effects of ß-D-Mannuronic acid in patients with Rheumatoid Arthritis
Phase 1
- Conditions
- Rheumatoid Arthritis.Seropositive Rheumatoid Arthritis
- Registration Number
- IRCT2014011213739N2
- Lead Sponsor
- Vice-Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Inclusion Criteria: 25-60 years old patients diagnosed with RA according to American College of Rheumatology Diagnostic Criteria after the initial visit by a specialist in rheumatology and parameters ESR, RF, CRP and Anti-CCP elected. Also each patient must sign written informed consent.
Exclusion Criteria
History of fever and infectious diseases, positive pregnancy test or lactation, other collagen- vascular diseases, other auto-immune diseases, malignancies, patients have enrolled another Clinical Trial study within last 4 weeks, other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of disease. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Taking history and Questionnaire.;Morning stiffness. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Taking history and Questionnaire.;The number of swollen joints. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination.;Pain. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination.
- Secondary Outcome Measures
Name Time Method